Print
Email
Print Edition Stories
Regenerative medicine firms make business of creating skin
MHT's Emerging Technologies Forum: Health IT and the Cloud
Synageva BioPharma Corp. has moved its headquarters from Waltham to Lexington, gaining more lab space for its rare disease drug treatments, the company reported today.
The company makes an enzyme replacement treatment, called SBC-102, for the rare childhood diseases Lysosomal Acid Lipase Deficiency, also known as Wolman Disease, and Cholesteryl Ester Storage Disease (CESD). SBC-102 is Synageva’s lead program.
In July, SBC-102 was granted orphan drug designation from the U.S. Food and Drug Administration, making Synageva eligible for benefits like grant funding for clinical trials, tax credits, waiver of the FDA fees and seven years of market exclusivity upon approval.
Synageva moved its headquarters to Waltham in 2008, following 10 years in Atlanta under a former name, AviGenics.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
